Surgalign Holdings, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Surgalign Holdings, Inc.
Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.
BioXpress Therapeutics and Abzena, two service providers with expertise in biosimilar development, have partnered to support biosimilar development for third party customers. The companies plan to offer a “flexible and innovative approach from small scale biosimilar development through to large scale manufacturing.”
The blockbuster drug is expected to see overall sales declines in the next few years, and biosimilar competition could come as soon as 2023.
Market Brief: Global Orthobiologics Market Will Reach $2.3Bn By 2023 With Highest Growth In Cartilage Replacement
The global market for orthobiologics for musculoskeletal soft tissue replacement and regeneration is expected to reach $2.3bn by 2023, according to a new report by Informa's Meddevicetracker. This highly competitive market, which is led by Arthrex and other large and smaller players, continues to grow amid the rising prevalence of musculoskeletal soft tissue injuries and osteoarthritis. High prices of implants, the limited availability of donated tissue and limited reimbursement for synthetic scaffolds are limiting growth in this market.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Other Names / Subsidiaries
- Paradigm Spine, LLC
- Regeneration Technologies, Inc.
- Tutogen Medical, Inc.
- Pioneer Surgical Technology, Inc.
- RTI Biologics, Inc.
- Zyga Technology
- RTI Surgical, Inc.